Immuron (ASX:IMC) reported global sales for its immune supplement, Travelan, of roughly AU$2.5 million in the December 2024 quarter, a surge of 249% year on year, according to a Friday filing with the Australian bourse.
Sales in Australia soared 315% to nearly AU$1.9 million, while North American sales climbed 141% to AU$652,000.
Global half-year sales jumped 70% to AU$4 million.
The biopharmaceutical company's shares climbed past 8% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.